TORONTO -- An investigational anti-fibrotic agent is showing promise in the treatment of idiopathic pulmonary fibrosis (IPF), a researcher said here.
ATS: Pirfenidone Slows IPF Lung DeclinesCourtesy MedPage Today Allergy & Immunology Tue, 05/20/2008 - 14:05
TORONTO -- An investigational anti-fibrotic agent is showing promise in the treatment of idiopathic pulmonary fibrosis (IPF), a researcher said here. More related itemsHouse Screening Confers Prenatal Lead Protection...
ASH: Presurgery Transfusion Cuts Risk in Sickle Cell...
AASLD: New PI Effective, Safe in HCV Trial (CME/CE)
|
Popular by tags WeekMonth |
Post new comment